Evidence map›Paper›PMID 36796863›Full record

Trial reportThe journal of sexual medicine2023

Unrecognized sexual dysfunction in gay and bisexual men after prostate cancer treatment: the antecedents and impact of anodyspareunia.

Christopher W Wheldon, Alex J Bates, Elizabeth J Polter, B R Simon Rosser, Aditya Kapoor, Kristine M C Talley, Ryan Haggart, Nidhi Kohli, Badrinath R Konety, Darryl Mitteldorf and 3 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The journal of sexual medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Christopher W WheldonDepartment of Social and Behavioral Sciences, College of Public Health, Temple University, Philadelphia, PA United States.
Alex J BatesDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States.ORCID 0000-0002-2447-4855
Elizabeth J PolterDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States.
B R Simon RosserDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States.
Aditya KapoorDepartment of Radiology, Trinity Teleradiology Services, Vancouver, BC, Canada.
Kristine M C TalleyAdult and Gerontological Health, University of Minnesota School of Nursing School, Minneapolis, Minnesota, United States.
Ryan HaggartDepartment of Urology, University of Minnesota, Minneapolis, Minnesota, United States.
Nidhi KohliDepartment of Educational Psychology, University of Minnesota, Minneapolis, Minnesota, United States.
Badrinath R KonetyDepartment of Urology, Rush Medical College, Chicago, Illinois.
Darryl MitteldorfMalecare Cancer Support, New York, New York, United States.
Michael W RossDepartment of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis, Minnesota, United States.
William WestDepartment of Writing Studies, University of Minnesota, Minneapolis, Minnesota, United States.
Morgan WrightDivision of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States.
University of Minnesota · USCancerCare · USRush University Medical Center · USTemple University · USTrinity Health · US

Funding

Minnesota Population Center Science and Technical CoreP2CHD041023 · NICHD · UNIVERSITY OF MINNESOTA · PI THERESA LOUISE OSYPUK · 2016 to 2026
$4.3M
Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer SurvivorsR01CA218657 · NCI · UNIVERSITY OF MINNESOTA · PI ROSSER, B R SIMON · 2017 to 2021
$3.1M
Interdisciplinary Population Health Science Training: Linking Multilevel Forces Across TimeT32HD095134 · NICHD · UNIVERSITY OF MINNESOTA · PI THERESA LOUISE OSYPUK, John Robert Warren · 2019 to 2026
$2.5M
NCI NIH HHS R01 CA218657NICHD NIH HHS P2C HD041023NICHD NIH HHS T32 HD095134NIH HHS R01CA218657
6 · The paper itself

Abstract

backgroundAnodyspareunia may be an adverse outcome of prostate cancer (PCa) treatment for gay, bisexual, and other men who have sex with men (GBM).

aimThe aims of this study were to (1) describe the clinical symptoms of painful receptive anal intercourse (RAI) in GBM following PCa treatment, (2) estimate the prevalence of anodyspareunia, and (3) identify clinical and psychosocial correlates.

methodsThis was a secondary analysis of baseline and 24-month follow-up data from the Restore-2 randomized clinical trial of 401 GBM treated for PCa. The analytic sample included only those participants who attempted RAI during or since their PCa treatment (N = 195). OUTCOMES: Anodyspareunia was operationalized as moderate to severe pain during RAI for ≥6 months that resulted in mild to severe distress. Additional quality-of-life outcomes included the Expanded Prostate Cancer Index Composite (bowel function and bother subscales), the Brief Symptom Inventory-18, and the Functional Assessment of Cancer Therapy-Prostate.

resultsOverall 82 (42.1%) participants reported pain during RAI since completing PCa treatment. Of these, 45.1% experienced painful RAI sometimes or frequently, and 63.0% indicated that the pain was persistent. The pain at its worst was moderate to very severe for 79.0%. The experience of pain was at least mildly distressing for 63.5%. Painful RAI worsened for a third (33.4%) of participants after completing PCa treatment. Of the 82 GBM, 15.4% were classified as meeting criteria for anodyspareunia. Antecedents of anodyspareunia included a lifelong history of painful RAI and bowel dysfunction following PCa treatment. Those reporting symptoms of anodyspareunia were more likely to avoid RAI due to pain (adjusted odds ratio, 4.37), which was negatively associated with sexual satisfaction (mean difference, -2.77) and self-esteem (mean difference, -3.33). The model explained 37.2% of the variance in overall quality of life. CLINICAL IMPLICATIONS: Culturally responsive PCa care should include the assessment of anodyspareunia among GBM and explore treatment options. STRENGTHS AND LIMITATIONS: This is the largest study to date focused on anodyspareunia among GBM treated for PCa. Anodyspareunia was assessed with multiple items characterizing the intensity, duration, and distress related to painful RAI. The external validity of the findings is limited by the nonprobability sample. Furthermore, the cause-and-effect relationships between the reported associations cannot be established by the research design.

conclusionsAnodyspareunia should be considered a sexual dysfunction in GBM and investigated as an adverse outcome of PCa treatment.

Indexed as

DyspareuniaProstatic NeoplasmsSexual and Gender MinoritiesSexual Dysfunction, PhysiologicalFemaleHomosexuality, MaleHumansMalePainQuality of LifeSexual Behavioragedcancer survivorGLBT personsnonheterosexual personsprostatic neoplasmssexual dysfunctionsexual minorities

Identifiers

PMID36796863
PMCPMC10078940
OpenAlexW4321015258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.